

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/380792777>

# Harnessing BRCA Advances: Revolutionizing Breast Cancer Diagnosis and Treatment

Article in *Haematology International Journal* · May 2024

DOI: 10.23880/hij-16000255

CITATIONS

0

READS

9

1 author:



[Emmanuel Ifeanyi Obeagu](#)

Kampala International University (KIU)

1,686 PUBLICATIONS 23,400 CITATIONS

SEE PROFILE



# Harnessing BRCA Advances: Revolutionizing Breast Cancer Diagnosis and Treatment

**Emmanuel Ifeanyi Obeagu\***

Department of Medical Laboratory Science, Kampala International University, Uganda

**\*Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com

## Review Article

Volume 8 Issue 1

Received Date: May 09, 2024

Published Date: May 23, 2024

DOI: 10.23880/hij-16000255

## Abstract

Advancements in understanding BRCA gene mutations have reshaped breast cancer management, ushering in a new era of precision oncology. This review explores the transformative impact of BRCA research on breast cancer diagnosis and treatment strategies, emphasizing the pivotal role of genetic testing, targeted therapies, and personalized medicine approaches. Harnessing BRCA advances offers unprecedented opportunities for early detection, risk stratification, and tailored treatment modalities, fundamentally altering the landscape of breast cancer care. Central to harnessing BRCA advances is the widespread adoption of genetic testing for BRCA mutations, enabling the identification of individuals at heightened risk of hereditary breast cancer. Genetic testing informs risk stratification and facilitates personalized screening and preventive interventions, including risk-reducing surgeries and enhanced surveillance protocols. Moreover, genetic testing guide's treatment decision-making by identifying candidates for targeted therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors, which have demonstrated efficacy in BRCA-mutated breast cancers, offering new avenues for precision medicine in oncology. The integration of targeted therapies tailored to BRCA-related breast cancer subtypes represents a paradigm shift in treatment approaches, providing novel strategies to optimize patient outcomes. PARP inhibitors have emerged as a promising therapeutic option for BRCA-mutated breast cancers, leading to improved progression-free survival and overall survival in metastatic settings. On-going research endeavours aim to elucidate molecular mechanisms of treatment response and resistance, paving the way for the development of innovative therapeutic strategies to address unmet clinical needs and further enhance the efficacy of precision oncology in breast cancer management.

**Keywords:** BRCA; Breast Cancer; Diagnosis; Treatment; Precision Medicine; Genetic Testing

**Abbreviations:** NGS: Next-Generation Sequencing; AIs: Aromatase Inhibitors; SERMs: Selective Estrogen Receptor Modulators.

## Introduction

Breast cancer stands as one of the most prevalent malignancies affecting women globally, with significant

implications for public health and healthcare systems worldwide. The elucidation of genetic factors underlying breast cancer predisposition has sparked a paradigm shift in our understanding of disease etiology and treatment strategies. Among these genetic determinants, mutations in the BRCA1 and BRCA2 genes have emerged as key contributors to hereditary breast cancer susceptibility [1-4]. BRCA1 and BRCA2 mutations, first identified in the early

1990s, have since become pivotal targets for research aimed at unravelling the genetic basis of breast cancer predisposition. These tumour suppressor genes play crucial roles in DNA repair mechanisms, maintaining genomic integrity and preventing the accumulation of deleterious mutations. However, germline mutations in BRCA1 and BRCA2 disrupt these essential functions, predisposing individuals to a significantly elevated lifetime risk of developing breast and ovarian cancers. The identification of BRCA mutations has profound implications for both affected individuals and their families, prompting intensified efforts to develop effective strategies for early detection, risk stratification, and targeted treatment interventions [5-7].

Central to harnessing BRCA advances in breast cancer management is the widespread adoption of genetic testing for BRCA mutations. Genetic testing enables the identification of individuals at increased risk of hereditary breast cancer, facilitating targeted screening and preventive interventions. Moreover, genetic testing informs treatment decision-making by guiding the selection of targeted therapies and informing prognosis. Advances in next-generation sequencing technologies have made genetic testing more accessible and affordable, allowing for broader implementation in clinical practice and population-based screening programs. Furthermore, genetic testing extends beyond the realm of cancer predisposition, providing valuable insights into familial cancer syndromes and informing risk assessment and management strategies for affected individuals and their relatives [8-11]. The integration of genetic testing into routine clinical practice has ushered in a new era of precision oncology, offering unprecedented opportunities for personalized breast cancer care. Genetic testing not only enables risk stratification and early detection of breast cancer but also informs treatment decisions tailored to the individual molecular profile of the tumour. Targeted therapies directed against BRCA-related breast cancer subtypes represent a paradigm shift in treatment approaches, providing novel strategies to optimize patient outcomes [12]. Poly (ADP-ribose) polymerase (PARP) inhibitors, in particular, have emerged as promising therapeutic options for BRCA-mutated breast cancers, demonstrating efficacy in both metastatic and early-stage disease settings. These targeted therapies capitalize on the underlying molecular vulnerabilities associated with BRCA mutations, exploiting synthetic lethality to selectively target tumour cells while sparing normal tissues. In addition to their role in treatment decision-making, BRCA mutations have significant implications for risk-reducing interventions and familial cancer risk management. Individuals with BRCA mutations face a substantially elevated lifetime risk of developing breast and ovarian cancers, necessitating proactive risk reduction strategies [13]. Risk-reducing surgeries, including prophylactic mastectomy and bilateral

salpingo-oophorectomy, have been shown to significantly reduce cancer risk in BRCA mutation carriers. Furthermore, risk-adapted screening protocols, incorporating breast MRI and ultrasound in addition to mammography, enable early detection of breast cancer in high-risk individuals, leading to improved outcomes and survival rates.

## Genetic Testing

Genetic testing has emerged as a cornerstone of breast cancer management, offering invaluable insights into hereditary factors predisposing individuals to the disease. Central to genetic testing in the context of breast cancer is the identification of mutations in the BRCA1 and BRCA2 genes, which confer a significantly elevated lifetime risk of developing breast and ovarian cancers. Genetic testing enables the detection of these pathogenic mutations, facilitating risk assessment, personalized screening protocols, and targeted treatment interventions. The implementation of genetic testing for BRCA mutations has undergone significant advancements in recent years, driven by technological innovations and increased awareness of hereditary cancer syndromes. Next-generation sequencing (NGS) technologies have revolutionized genetic testing, enabling the rapid and cost-effective analysis of multiple genes associated with hereditary cancer predisposition. This has facilitated broader adoption of multigene panel testing, allowing for comprehensive assessment of genetic risk factors beyond BRCA1 and BRCA2, including other high-penetrance genes such as TP53, PTEN, and PALB2, as well as moderate-penetrance genes like ATM and CHEK2 [14-18].

The integration of genetic testing into clinical practice has profound implications for breast cancer risk stratification and preventive interventions. Identification of BRCA mutations informs personalized risk assessment and enables tailored management strategies for mutation carriers and their families. Risk-reducing interventions, including prophylactic mastectomy and bilateral salpingo-oophorectomy, have been shown to significantly reduce the risk of breast and ovarian cancers in BRCA mutation carriers. Moreover, risk-adapted screening protocols, incorporating breast MRI and ultrasound in addition to mammography, enable early detection of breast cancer in high-risk individuals, leading to improved outcomes and survival rates.10-11 Genetic testing also plays a critical role in guiding treatment decisions for individuals with BRCA-related breast cancer. Identification of BRCA mutations informs the selection of targeted therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors, which have demonstrated efficacy in BRCA-mutated breast cancers. PARP inhibitors exploit the synthetic lethality resulting from BRCA deficiency, selectively targeting tumour cells while sparing normal tissues. Furthermore, on-going research efforts aim to identify additional therapeutic targets

and biomarkers of treatment response to further optimize treatment outcomes and overcome resistance mechanisms in BRCA-related breast cancer [19-23].

### Risk Stratification and Prevention

Risk stratification and preventive interventions play pivotal roles in mitigating the burden of breast cancer, particularly in individuals with hereditary predisposition due to BRCA gene mutations. Effective risk assessment strategies enable the identification of individuals at elevated risk, facilitating targeted preventive interventions aimed at reducing cancer incidence and mortality. BRCA mutations confer a significantly elevated lifetime risk of developing breast and ovarian cancers, underscoring the importance of proactive risk reduction strategies in mutation carriers and their families [24]. Risk-reducing interventions, including prophylactic mastectomy and bilateral salpingo-oophorectomy, have been shown to substantially reduce cancer risk in BRCA mutation carriers. Prophylactic mastectomy reduces the risk of breast cancer by up to 90% in BRCA mutation carriers, while bilateral salpingo-oophorectomy significantly reduces the risk of ovarian cancer and also lowers the risk of breast cancer by approximately 50% [25]. In addition to surgical interventions, chemoprevention strategies offer alternative options for reducing cancer risk in high-risk individuals. Selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, and aromatase inhibitors (AIs), such as exemestane, have been shown to reduce the incidence of breast cancer in women at increased risk, including BRCA mutation carriers. These agents act by interfering with estrogen signaling pathways, thereby inhibiting the growth and proliferation of hormone-sensitive breast cancer cells.

Risk-adapted screening protocols complement preventive interventions by enabling early detection of breast cancer in high-risk individuals. Current guidelines recommend enhanced surveillance protocols for individuals with BRCA mutations, including annual breast MRI in addition to mammography, starting at an earlier age (typically around age 25 or 30). Breast MRI offers superior sensitivity for detecting invasive breast cancers, particularly in young women with dense breast tissue, thereby improving the chances of detecting tumours at an early and potentially curable stage [23]. Moreover, risk stratification based on genetic testing results informs personalized screening recommendations and enables tailored surveillance protocols for individuals at different levels of risk. Close monitoring of breast tissue changes, regular clinical breast exams, and breast self-awareness education further empower individuals to actively participate in their breast health management and facilitate early detection of potential abnormalities. Despite the efficacy of risk stratification and

preventive interventions, challenges remain in optimizing risk assessment and implementing preventive measures in clinical practice. Barriers to risk stratification and prevention include limited access to genetic testing, disparities in healthcare access and resources, and psychosocial factors influencing decision-making regarding risk-reducing interventions. Addressing these challenges requires a multidisciplinary approach, encompassing education, advocacy, and policy initiatives aimed at promoting equitable access to genetic testing and preventive interventions, as well as providing comprehensive support services for individuals and families affected by hereditary breast cancer.

### Targeted Therapies and Precision Medicine

Targeted therapies capitalize on the underlying molecular vulnerabilities associated with BRCA mutations, exploiting synthetic lethality to selectively target tumour cells while sparing normal tissues [24]. Among these targeted therapies, poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutic options for BRCA-mutated breast cancers, demonstrating efficacy in both metastatic and early-stage disease settings. PARP inhibitors represent a paradigm shift in breast cancer treatment, offering a novel mechanism of action that exploits the inherent DNA repair defects characteristic of BRCA-mutated tumours [25]. BRCA-mutated cancers exhibit deficiencies in homologous recombination repair, rendering them highly sensitive to inhibition of the PARP enzyme, which plays a crucial role in base excision repair. By inhibiting PARP activity, PARP inhibitors induce synthetic lethality in BRCA-mutated tumour cells, leading to DNA damage accumulation, cell cycle arrest, and ultimately, cell death. Beyond their role in metastatic disease, PARP inhibitors are being investigated as adjuvant and neoadjuvant therapies in early-stage BRCA-mutated breast cancers, aiming to improve outcomes and reduce the risk of disease recurrence. Preliminary data from clinical trials suggest promising results, with PARP inhibitors demonstrating efficacy in reducing tumour burden and increasing rates of pathologic complete response in the neoadjuvant setting. Despite the remarkable progress made in targeted therapies for BRCA-related breast cancer, challenges remain in optimizing treatment selection, identifying biomarkers of treatment response, and managing adverse effects associated with therapy. Strategies for mitigating resistance mechanisms, refining patient selection criteria, and personalizing treatment regimens based on individual tumor characteristics represent areas of on-going research and clinical investigation.

### Conclusion

The transformative impact of BRCA advances on breast cancer diagnosis and treatment heralds a new era of

precision oncology, offering unprecedented opportunities for personalized care and improved outcomes. Genetic testing for BRCA mutations has revolutionized risk assessment, enabling early identification of individuals at heightened risk of hereditary breast cancer and informing tailored preventive interventions. Proactive risk reduction strategies, including risk-reducing surgeries, chemoprevention, and enhanced surveillance protocols, have proven effective in reducing cancer incidence and mortality in high-risk individuals. Moreover, targeted therapies tailored to BRCA-related breast cancer subtypes have reshaped the treatment landscape, providing novel options for precision medicine approaches. PARP inhibitors, in particular, have demonstrated remarkable efficacy in both metastatic and early-stage disease settings, expanding treatment options and improving survival rates for patients with BRCA-mutated breast cancers. On-going research efforts aim to further optimize treatment strategies, identify biomarkers of treatment response, and overcome resistance mechanisms, paving the way for continued advancements in breast cancer care.

## References

1. Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. *Cancer epidemiology* 33(5): 315-318.
2. Economopoulou P, Dimitriadis G, Psyrri A (2015) Beyond BRCA: new hereditary breast cancer susceptibility genes. *Cancer treatment reviews* 41(1): 1-8.
3. Obeagu EI, Obeagu GU (2024) Breast cancer: A review of risk factors and diagnosis. *Medicine* 103(3): e36905.
4. Obeagu EI, Babar Q, Vincent CC, Udenze CL, Eze R, et al. (2021) Therapeutic targets in breast cancer signaling: A review. *Journal of Pharmaceutical Research International* 33(56A): 82-99.
5. Obeagu EI, Obeagu GU (2024) BRCA Mastery Redefining Breast Cancer Care through Cuttingedge Diagnosis and Management. *Elite Journal of Medicine* 2(2): 55-66.
6. Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, et al. (2023) Prostate cancer risk screening and management in patients with germline BRCA1/2 mutations. *Nat Rev Urol* 20(4): 205-216.
7. Trapani D, Sandoval J, Aliaga PT, Ascione L, Giachetti PP, et al. (2023) Screening Programs for Breast Cancer: Toward Individualized Risk-Adapted Strategies of Early Detection. *Cancer Treat Res* 188: 63-88.
8. Sundar S, Singh P, Frampton J, Trimble E, Rajaraman P, et al. (2018) Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research. *The Lancet Oncology* 19(2): 102-112.
9. Mohamed QH, Obeagu EI (2024) Genetic Heterogeneity in Breast Cancer Implications. *Elite Journal of Health Science* 2(1): 20-24.
10. Mohamed AF, Obeagu EI (2024) Genetic Influence on Breast Cancer Progression A Molecular Perspective. *Elite Journal of Medical Science* 2(1): 19-22.
11. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU (2022) An Insight of Interleukin-6 and Fibrinogen In Regulating the Immune System. *J Biomed Sci* 11(10): 83.
12. Devico MN, Kroening G, Dayyani F, Zell JA, Lee FC, et al. (2022) BRCA mutated pancreatic cancer: from discovery to novel treatment paradigms. *Cancers* 14(10): 2453.
13. Biber S, Seven M, Jiang J, Schaik S, Dwyer AA (2022) Impact of BRCA Status on Reproductive Decision Making and Self Concept A Mixed-Methods Study Informing the Development of Tailored Interventions. *Cancers* 14(6): 1494.
14. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO, Uduchi IO (2021) Advances in Therapeutic Strategies of Immunotherapy in Cancer Treatment. *World Journal of Pharmacy and Pharmaceutical Sciences* 10(8): 2144-2164.
15. Aizaz M, Khan M, Khan FI, Munir A, Ahmad S, et al. (2023) Burden of Breast Cancer: Developing Countries Perspective. *International Journal of Innovative and Applied Research* 11(1): 31-37.
16. Obeagu EI, Obeagu GU (2024) Breast cancer a review of risk factors and diagnosis. *Medicine* 103(3): 36905.
17. Obeagu EI, Obeagu GU (2024) Breastfeeding's protective role in alleviating breast cancer burden: A comprehensive review. *Ann Med Surg (Lond)* 86(5): 2805-2811.
18. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OP, et al. (2023) Biomarkers of breast cancer Overview. *Int J Curr Res Biol Med* 8(1): 8-16.
19. Obeagu EI, Obeagu GU (2024) Breaking Ground PARP Inhibitors and Their Efficacy in Breast Cancer Stages. *Elite Journal of Medicine* 2(2): 42-54.
20. Obeagu EI, Obeagu GU (2024) BRCA Mastery Redefining Breast Cancer Care through Cutting edge Diagnosis and Management. *Elite Journal of Medicine* 2(2): 55-66.
21. Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, et al (1996) Role of BRCA1 mutation

screening in the management of familial ovarian cancer. American journal of obstetrics and gynecology 175(3P1): 738-746.

22. Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, et al. (2010) Prophylactic and risk-reducing bilateral salpingo-oophorectomy recommendations based on risk of ovarian cancer. Obstet Gynecol 116(3): 733-743.
23. Mann RM, Cho N, Moy L (2019) Breast MRI: state of the

art. Radiology 292(3): 520-536.

24. Labrie M, Brugge JS, Mills GB, Zervantonakis IK (2022) Therapy resistance opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 22(6): 323-339.
25. Brown JS, Carrigan B, Jackson SP, Yap TA (2017) Targeting DNA repair in cancer beyond PARP inhibitors. Cancer discovery 7(1): 20-37.